There are many variables when it comes to diagnosing and treating prostate cancer, so knowledge really is key >> http://ow.ly/Hlwd30a8EOz
This could have a really positive impact on the fight against brain cancers: http://ow.ly/BHb3309qXbk
More exciting progress in the treatment of bowel cancers: http://ow.ly/qtRn309qWYJ
We are excited to announce our move into a new purpose designed office at Richmond Quarter in East Fremantle, Western Australia. The office will house our management, marketing, data and general administration teams. For information about our services, visit >>> theranostics.com.au.
Theranostics Australia’s A/Prof Nat Lenzo will be presenting on clinical patient experience for Lutetium-177 PSMA therapy at the Eckert & Ziegler and Imaxeon “Symposium on Theranostics”, following the conclusion of the 4th Theranostics World Congress in Melbourne, VIC.
Theranostics Australia’s A/Prof Nat Lenzo has joined the National Imaging Facility (NIF) as a member of their Industry Advisory Panel. NIF is an Australian-wide network of world-class imaging infrastructure that merges cutting-edge imaging technologies with highly specialised expertise from 10 universities and research institutes, along with ANSTO, to develop advanced imaging solutions and drive innovation. The NIF Industry Advisory Panel will provide insight and consultation to NIF to improve strategies for increasing collaboration with national and international commercial parties.
Theranostics Australia is very pleased to announce the formation of “Sydney Theranostics” based at Macquarie Medical Imaging, Ground Floor, Macquarie University Hospital, Sydney, NSW. Gallium-68 imaging, Lutetium-177 and other radionuclide therapies are planned to commence December 2016. For further information, contact Dr Pon Anura via email – email@example.com.